Hansa Biopharma AB (publ) (HNSBF)
USD 3.0
(-9.09%)
USD 3.0
(-9.09%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 134.7 Million SEK | 119.11% |
| 2022 | -705.08 Million SEK | -14.47% |
| 2021 | -615.96 Million SEK | 45.7% |
| 2020 | -1.13 Billion SEK | -558.58% |
| 2019 | -172.23 Million SEK | 60.75% |
| 2018 | -438.86 Million SEK | 24.42% |
| 2017 | -580.67 Million SEK | -171.93% |
| 2016 | -213.54 Million SEK | -21.61% |
| 2015 | -175.59 Million SEK | -1652.07% |
| 2014 | -10.02 Million SEK | -2439.51% |
| 2013 | 428.38 Thousand SEK | 102.28% |
| 2012 | -18.76 Million SEK | -1153.25% |
| 2011 | 1.78 Million SEK | 903.62% |
| 2010 | -221.66 Thousand SEK | -103.0% |
| 2009 | 7.38 Million SEK | 224.88% |
| 2008 | -5.91 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 405.65 Million SEK | 201.14% |
| 2024 Q2 | 269.48 Million SEK | -33.57% |
| 2024 Q3 | 389.4 Million SEK | 50.53% |
| 2023 Q4 | 134.7 Million SEK | 522.5% |
| 2023 FY | 134.7 Million SEK | 119.11% |
| 2023 Q1 | -462.41 Million SEK | 34.42% |
| 2023 Q2 | -236.66 Million SEK | 48.82% |
| 2023 Q3 | 21.64 Million SEK | 109.14% |
| 2022 Q1 | -485.46 Million SEK | 21.19% |
| 2022 Q2 | -485.26 Million SEK | 0.04% |
| 2022 FY | -705.08 Million SEK | -14.47% |
| 2022 Q3 | -424.26 Million SEK | 12.57% |
| 2022 Q4 | -705.08 Million SEK | -66.19% |
| 2021 Q2 | -879.87 Million SEK | 13.13% |
| 2021 Q1 | -1.01 Billion SEK | 10.71% |
| 2021 FY | -615.96 Million SEK | 45.7% |
| 2021 Q3 | -748.44 Million SEK | 14.94% |
| 2021 Q4 | -615.96 Million SEK | 17.7% |
| 2020 Q1 | -140.59 Million SEK | 18.37% |
| 2020 Q4 | -1.13 Billion SEK | 7.93% |
| 2020 Q3 | -1.23 Billion SEK | -773.87% |
| 2020 Q2 | -140.97 Million SEK | -0.27% |
| 2020 FY | -1.13 Billion SEK | -558.58% |
| 2019 Q3 | -219.66 Million SEK | 28.75% |
| 2019 Q1 | -324.7 Million SEK | 26.01% |
| 2019 Q2 | -308.3 Million SEK | 5.05% |
| 2019 FY | -172.23 Million SEK | 60.75% |
| 2019 Q4 | -172.23 Million SEK | 21.59% |
| 2018 Q4 | -438.86 Million SEK | -729.88% |
| 2018 Q2 | -59.43 Million SEK | 40.23% |
| 2018 Q1 | -99.44 Million SEK | 82.88% |
| 2018 FY | -438.86 Million SEK | 24.42% |
| 2018 Q3 | -52.88 Million SEK | 11.03% |
| 2017 Q3 | -25.3 Million SEK | 60.72% |
| 2017 Q2 | -64.42 Million SEK | 45.29% |
| 2017 Q1 | -117.75 Million SEK | 44.85% |
| 2017 FY | -580.67 Million SEK | -171.93% |
| 2017 Q4 | -580.67 Million SEK | -2194.8% |
| 2016 Q3 | -53.37 Million SEK | -58.44% |
| 2016 Q4 | -213.54 Million SEK | -300.08% |
| 2016 FY | -213.54 Million SEK | -21.61% |
| 2016 Q2 | -33.68 Million SEK | 42.02% |
| 2016 Q1 | -58.1 Million SEK | 66.91% |
| 2015 Q1 | -1.96 Million SEK | 80.43% |
| 2015 Q2 | -209.06 Million SEK | -10561.35% |
| 2015 Q4 | -175.59 Million SEK | 8.82% |
| 2015 Q3 | -192.58 Million SEK | 7.88% |
| 2015 FY | -175.59 Million SEK | -1652.07% |
| 2014 Q4 | -10.02 Million SEK | 0.0% |
| 2014 Q1 | 90 Thousand SEK | -78.99% |
| 2014 FY | -10.02 Million SEK | -2439.51% |
| 2014 Q2 | -25.21 Million SEK | -28118.09% |
| 2013 Q4 | 428.38 Thousand SEK | -23.5% |
| 2013 FY | 428.38 Thousand SEK | 102.28% |
| 2013 Q2 | -9.13 Million SEK | 0.0% |
| 2013 Q3 | 560 Thousand SEK | 106.13% |
| 2012 Q2 | -27.82 Million SEK | 0.0% |
| 2012 Q4 | -18.76 Million SEK | 0.0% |
| 2012 FY | -18.76 Million SEK | -1153.25% |
| 2011 Q4 | 1.78 Million SEK | 0.0% |
| 2011 FY | 1.78 Million SEK | 903.62% |
| 2011 Q2 | -12.22 Million SEK | 0.0% |
| 2010 Q2 | -9.45 Million SEK | 0.0% |
| 2010 Q4 | -221.66 Thousand SEK | 0.0% |
| 2010 FY | -221.66 Thousand SEK | -103.0% |
| 2009 FY | 7.38 Million SEK | 224.88% |
| 2009 Q4 | 7.38 Million SEK | 0.0% |
| 2009 Q2 | -94.7 Thousand SEK | 0.0% |
| 2008 FY | -5.91 Million SEK | 0.0% |
| 2008 Q4 | -5.91 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Qrons Inc. | 351.42 Thousand USD | -38231.716% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 2236.688% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 54065.227% |
| Adynxx, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -677949.026% |
| Capstone Therapeutics Corp. | 20.27 Million USD | -564.372% |
| BioStem Technologies, Inc. | 4.47 Million USD | -2912.247% |
| CSL Limited | 10.52 Billion USD | 98.72% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -2284.9% |
| Evofem Biosciences, Inc. | 42.79 Million USD | -214.79% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | -210.144% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -21108.281% |
| Skye Bioscience, Inc. | -5.72 Million USD | 2454.463% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 660174.481% |
| Rebus Holdings, Inc. | 305 Thousand USD | -44066.557% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 10283153.435% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -21544.568% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -754.584% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -3171.181% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -33422.044% |
| SQZ Biotechnologies Company | -36.23 Million USD | 471.731% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -5907.761% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -14428.692% |
| Mesoblast Limited | 55.85 Million USD | -141.16% |
| Marizyme, Inc. | 18.56 Million USD | -625.445% |
| Genus plc | 190.6 Million USD | 29.324% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -5924.961% |
| Pharming Group N.V. | 109.8 Million USD | -22.68% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -15559.333% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -10997.235% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -19710.0% |
| ContraFect Corporation | -6.02 Million USD | 2335.446% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -99951.248% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -11558.7% |
| IMV Inc. | 7.67 Million USD | -1656.178% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -2348.392% |
| MultiCell Technologies, Inc. | 90.04 USD | -149608962.639% |
| ONE Bio Corp. | 9.04 Million USD | -1390.127% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 18453.139% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -940.538% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -9747.285% |
| Q BioMed Inc. | 4.06 Million USD | -3217.924% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | -340.885% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -13267.655% |
| Biomind Labs Inc. | 711.4 Thousand USD | -18835.567% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | -122.49% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -6637.448% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -951.865% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -37349.056% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -96254.897% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -6017.582% |
| GB Sciences, Inc. | 1.74 Million USD | -7609.424% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 73395.319% |
| HST Global, Inc. | 96.79 Thousand USD | -139071.221% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -65223.421% |
| Halberd Corporation | 144.72 Thousand USD | -92981.17% |
| Enzolytics Inc. | 981.65 Thousand USD | -13622.526% |
| Agentix Corp. | 37.63 Thousand USD | -357870.822% |
| Resverlogix Corp. | 6.45 Million USD | -1988.172% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 20113.401% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 106.64% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 386.54% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -1805.085% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -4873.317% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 1623.861% |
| AVAX Technologies, Inc. | -5.9 Million USD | 2381.946% |
| Zenith Capital Corp. | 10.06 Thousand USD | -1338413.514% |
| Genscript Biotech Corporation | -1.06 Billion USD | 112.692% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -67108.829% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -5545.687% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -81784.882% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 735485.959% |
| Kadimastem Ltd | -253.1 Thousand USD | 53322.811% |
| Helix BioMedix, Inc. | -2.57 Million USD | 5341.491% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -66834.322% |
| LadRx Corporation | -2.03 Million USD | 6714.783% |
| Cell Source, Inc. | 9.23 Million USD | -1359.147% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -21108.281% |
| NovAccess Global Inc. | 2.17 Million USD | -6083.62% |
| Affymax, Inc. | -5.59 Million USD | 2506.789% |
| Itoco Inc. | 228.3 Thousand USD | -58903.526% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -98958.012% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -2617.531% |
| Mobile Lads Corp. | 484.23 Thousand USD | -27718.897% |
| CytoDyn Inc. | 20.26 Million USD | -564.831% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 20820501.855% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 1453521.001% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -1648.092% |
| SYBLEU INC | 473.71 Thousand USD | -28336.567% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -2922.377% |
| International Stem Cell Corporation | 2.59 Million USD | -5101.081% |
| Bioxytran, Inc. | 1.89 Million USD | -6993.949% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -215733.24% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -6076.716% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -3822.772% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -1474.98% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -17335.514% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 10876.64% |
| Neutra Corp. | 52.18 Thousand USD | -258025.587% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 5512.133% |
| PureTech Health plc | -167.19 Million USD | 180.568% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 55103.512% |
| IXICO plc | -4.44 Million USD | 3130.833% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -919.048% |
| Gelesis Holdings, Inc. | 54.85 Million USD | -145.589% |
| CSL Limited | 10.52 Billion USD | 98.72% |
| Cellectis S.A. | -43.81 Million USD | 407.42% |